Podcasts about newsletterto

This week we preview the BIO International Convention, starting next week in San Diego. This is the key partnering event of the year where biotechs connect with pharmaceutical companies and investors in partnering meetings, all to advance and fund innovative therapies.My guest is Werner Lanthaler, Founder and CEO of WLAN Holding. Werner spent 15 years as CEO of Evotec SE, scaling the company from 200 employees and €40 million revenue to over 5,000 staff and €800 million. He previously served as CFO of Intercell AG, overseeing its IPO and vaccine launch and today he leads investments and advisory in high-tech life sciences.Werner explains why partnering events like BIO are critical to advancing science in biopharma. He shares practical advice on how biotechs can prepare before the event, succeed on site, and follow up to turn meetings into partnerships. He offers clear, actionable strategies to optimize your BIO experience.01:36              Meet Werner Lanthaler06:48              The power of partnering08:55              Uncovering unexpected value13:43              Irreplaceable in-person trust17:06              Smart pre-event planning21:00              Strategic targeting24:02              Relationship-first meetings30:18              The importance of prompt, persistent follow-upInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: Special Episode: The 2025 BIO International ConventionThe ABC of biotech partnershipsHow to optimize your biotech company for partnering, licensing, and business success

Today we're diving into the world of corticosteroids and hormonal therapies — essential APIs that treat everything from asthma and autoimmune diseases to diabetes and endocrine disorders. These molecules may be decades old, but their manufacturing remains highly complex and critical to patients worldwide.Our guest is Olivier Roux, a Senior Director at Curia. He shares how Curia partners with both startups and big pharma to simplify steroid API challenges, solve supply issues, and prepare for next-generation innovations. If you want to understand what it really takes to bring these life-changing therapies to patients, stay tuned — this conversation is packed with insights you won't want to miss.01:39 Meet Olivier Roux02:20 What corticosteroids and hormonal therapies are04:40 Evolution of steroidal hormonal therapies05:50 Common uses of corticosteroids today07:40 Key drivers of market growth10:06 Curia's agile outsourcing solutions for steroids16:05 Importance of particle size control for steroids17:18 Aseptic processing and high potency handlingThis episode was produced with the support of Curia. Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: Eight rare autoimmune diseases biotechs are fighting to treatA clearer path to relief: sinusitis treatments on the wayAsthma study suggests lung scarring may be reversible 

Welcome to episode 200!Today I'm delighted to welcome back a very special guest: Joachim Eeckhout, the co-founder of Labiotech, co-owner of Knowbio, and founder of The Science Marketer.Joachim tells the Labiotech story, one of vision, persistence, and a deep belief that the European life-sciences sector deserved better storytelling. We go back to the very beginning with someone who was there: the frustrations, a bike tour of France that became legendary, the leap to Berlin, the fundraising rounds, the acquisition, and the launch of this very podcast.We'll also hear where Joachim is today with his new ventures, his candid take on the current biotech media landscape in Europe, and what he sees coming next for science communication and media in our industry.01:30: Meet Joachim Eeckhout02:19: Early attraction to media creation04:32: Founding story of Labiotech platform06:35: Bike tour visiting biotech CEOs11:21: Identifying larger European market opportunity19:55: Raising seed funding for growth24:20: Acquisition by Inpart in 202130:48: Current work with Knowbio38:57: Future plans for Knowbio and biotech mediaInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: Connecting the R&D ecosystem: 150 days into the integration of Inova, IN-PART and LabiotechWe raised our second financing round to become the largest biotech media

Today we welcome Dr. Daniel Vitt, CEO of Immunic Therapeutics. With World MS Day being tomorrow, the 30th of May, this is the perfect moment to focus on multiple sclerosis — a disease that affects nearly three million people worldwide and still leaves many patients searching for better options.In today's episode Daniel shares his own journey into biotechnology, walk us through what life with MS really looks like for patients, and explain the science behind Immunic's most advanced program, IMU-838. We discuss what makes Immunic's oral therapy different from today's treatments, uncover the latest data from the CALLIPER and ENSURE trials, and talk about what the future of MS care could look like.01:22 Meet Daniel Vitt04:54 Understanding multiple sclerosis07:53 Evolution of the MS treatment landscape12:08 Immunic's lead MS therapy explained22:57 World MS Day and what's next for ImmunicInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: 11 neuroscience biotech companies you should know aboutThe emergence of BTK inhibitors in multiple sclerosis treatment: Companies close in on approvalSix biotech companies advancing multiple sclerosis therapies

Today I am welcoming two guests: Quin Wills, CEO of Ochre Bio, a biotech developing RNA therapies for chronic liver disease using AI models, and Stéphane Barges, CEO of Lexogen, an RNA transcriptomics company and NGS service provider. It's a deep dive into cutting edge transcriptomics, human-first data, and artificial intelligence.00:55: The challenges of liver disease04:44: How Lexogen supports NGS drug discovery07:29: Major transcriptomics developments10:05: Designing high quality AI data15:47: How the Ochre-Lexogen partnership began17:17: Why a specialist partner is essential for scale18:21: Lexogen delivers on the massive sequencing project21:50: Why high quality data is crucial27:02: Lexogen's role in AI discovery34:51: Future plans and directionsThis episode was produced with the support of Lexogen. Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: Deep phenotyping brings accuracy to precision medicineSpatial Transcriptomics: A window into diseaseSpatial Transcriptomics Landscape Shifts With Two Major Acquisitions

Today, we're digging into a topic that's getting a lot more attention lately, how early decisions in cell therapy end up shaping or complicating everything that comes later. Our episode today is Freeze Variability, Not Progress, How to Strengthen Your Cell Therapy Supply Chain from the Start, and we're going to challenge a few long-held beliefs about how starting material should be handled. My guest today is Dominic Clarke, Vice President of Technical Operations for IntegriCell at Cryoport Systems. Dominic has spent years in the trenches building and scaling cell therapy processes from early development through commercialization. So, he's seen where things break and what actually works. I hope you enjoy my conversation with Dominic Clark.01:07    Meet Dominic Clarke and Cryoport Systems06:24   Fresh cells versus frozen cells08:21    Why teams switch to cryopreservation late12:37    The challenge of variability16:47    IntegriCell when you already have a process in place22:17    An argument for cryopreservation based on data25:56   The future of IntegriCell and Cryoport SystemsThis episode is brought to you with the support of Cryoport Systems.Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: IntegriCell® CryopreservationCryoport Systems on the state of the ATMP market and the importance of supply chain resilienceCracking the code: Delivering biotherapeutics successfully across EMEA

Today, we dive into the future of lab management with Ryan Cawood, CEO and co-founder of Lab Thread. Ryan's journey spans groundbreaking work in virotherapy and gene delivery during his D.Phil at Oxford, to founding OXGENE, a cell and gene therapy innovator acquired by WuXi Advanced Therapies in 2021.We'll explore the frustrations of fragmented lab tools that inspired Lab Thread's integrated digital solution—combining ELN, LIMS, molecular biology, and collaboration in one seamless platform. We'll uncover how it boosts reproducibility, ensures compliance, and frees scientists for innovation, with accessible pricing for academics and biotechs.I hope you enjoy Ryan's insights on evolving digital workflows and accelerating breakthroughs in the lab.01:51: Meet Ryan Cawood02:31: Frustrations with early digital tools.03:19: Daily lab organization challenges.06:50: Time lost to admin tasks.11:09: Genesis of the Lab Thread concept.13:53: Integrated workflow functionality explained.17:23: Enhancing experiment reproducibility methods.20:37: Achieving compliance standards easily.26:10: The future of digital lab management.28:33: Accelerating scientific breakthroughs.This episode is brought to you with the support of Lab Thread.Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: Lab Thread - Your Lab, ConnectedHiding in plain sight: how to solve bioscience's software problemLab chaos and digital dreams

This week we dive into the Beyond Biotech archive to bring you a discussion with Dr Stanley Qi, the founder of Epicrispr.Epicrispr is an epigenetic editing company, leveraging the power of CRISPR without cutting DNA. The company's proprietary Gene Expression Modulation System (GEMS) includes the smallest Cas protein known to work in human cells, enabling in vivo or ex vivo delivery via a single viral vector. In this episode we discuss epigenetic editing, why it's reversible, and how it can treat FSHD and other conditions. 01:43 Meet Stanley Qi03:32 Founding Epicrispr05:53 CRISPR interference and epigenome explained10:04 Overview of GEMS gene modulation system11:28 Reversibility and safety of epigenetic edits18:42 Strategy for tackling multiple disease conditions23:27 Clinical trial plans for EPI-321 candidate30:06 Looking forwardThis episode is brought to you with the support of MedChemExpress.Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: Could CRISPR really cure these diseases?10 gene therapy companies you should know aboutCRISPR technology's next wave: Ten companies to watch

Today we're joined by Patrick Andre, Chief Scientific Officer at Diagonal Therapeutics.A trained vascular biologist, Patrick's career spans groundbreaking work at Pfizer, Acceleron, Pliant Therapeutics, and earlier companies, where he focused on TGF-β superfamily signaling and receptor pathways that keep blood vessels healthy. Now at Diagonal, he's leading a bold mission: developing clustering antibodies that correct the root cause of serious genetic vasculopathies, rather than just managing symptoms.In this episode, Patrick walks us through his personal journey into science, the company's DIAGONAL platform, and their lead program DIAG723, which recently received Orphan Drug Designation for the rare disease HHT, and is advancing toward the clinic. We also discuss Diagonal's oversubscribed $125 million Series B financing that closed in January 2026, and what clustering antibodies could mean for patients with HHT, pulmonary arterial hypertension, and beyond.01:33 Meet Patrick Andre08:01 Diagonal's mission11:39 What are clustering antibodies16:05 Receptor clustering benefits for HHT and PAH20:24 Preclinical data on preventing and reversing HHT pathology22:39 The impact of the $125 Million Series B financing roundInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: Vaderis emerges from stealth to start HHT trialPulmonary hypertension after Winrevair: where GSK's $950M bet fitsNew treatment for pulmonary hypertension: what biotech holds in store?

Our guest today is Thierry Laugel, Managing Partner of Kurma & Chairman of Argobio. With a PharmD, PhD in pharmacology, and an INSEAD MBA, Thierry has spent more than two decades bridging cutting-edge science and commercial success—first in pharma R&D, then as co-founder of Kurma Partners, and now leading Argobio's unique venture-builder model.Since raising €50 million in 2021, Argobio has co-founded and accelerated several companies from top European academic labs. Three of them—Enodia, Laigo Bio, and Elkedonia—have already closed seed rounds totaling more than €43 million, advancing novel platforms in targeted protein degradation, precision membrane protein degraders, and non-hallucinogenic neuroplasticity enhancers for depression. Thierry shares how Argobio reduces execution risk, embeds operational expertise, and turns promising science into investable companies that can compete worldwide. 04:02 Blending pharmacology expertise with business07:50 Vision behind starting Kurma Partners12:53 Launching Argobio to address gaps in European biotech 17:40 What makes the Argobio operational venture builder model unique25:02 Criteria for selecting academic scientific breakthroughs27:34 Changing dynamics of commercializing European research35:30 Europe vs US biotech investment climates37:47 Role of venture studios in Europe's biotech futureInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: M Ventures: pharma CVC and biotech innovation in 2026Inside Flagship Pioneering's strategy: How this VC turns ideas into biotech giantsVenture capital co-creation: The next big thing in biotech investment?

Today, we're exploring the transformative potential of AI in biopharma—separating hype from reality, and zooming in on the complexities of single-cell omics data.Our guest is Parashar Dhapola, co-founder and CEO of Nygen Analytics, a Lund-based startup spun out from Sweden's vibrant single-cell genomics ecosystem. With a PhD in computational genomics from Lund University, Parashar has pioneered efficient algorithms for analyzing millions of cells, turning raw data into actionable insights for drug discovery.Join us as we discuss where AI truly delivers in biopharma, the persistent gaps in exploratory data analytics, and the critical bottlenecks in single-cell annotation. In a world abounding in AI hype, Parashar helps us cut through the noise and point out paths to data driven success.01:00 Meet Parashar Dhapola05:45 AI in biopharma09:29 AI automation vs. new capabilities11:28 What makes single-cell omics data different18:46 Risks of incorrect cell annotation34:37 Future of single-cell analyticsThis episode is produced with the support of Nygen Analytics. Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: CyteType - AI powered cell type annotationBehind the Cure51 deal: Is NVIDIA becoming biotech's AI infrastructure?The past, present, and future of genome sequencing

This week we welcome Magdalena Tyrpien, CEO, Co-Founder and President of Nionyx Bio, just days after the company took first place in the BIO-Europe Spring Startup Spotlight competition in Lisbon.With a background that includes leading Forge Biologics through its $620 million acquisition, Magdalena is now steering Nionyx toward a bold new chapter in gene therapy for kidney disease. In this episode we explore her journey into biotech, the science behind Nionyx's proprietary AAV capsid platform and Kidney Atlas, what it took to win the Startup Spotlight, and what the victory means for the young company's future.·  01:25 – Meet Magdalena Tyrpien·  07:10 – The Nionyx mission·  15:29 – The 2026 BIO-Europe Spring Startup Spotlight·  22:23 – Looking forward and future milestonesInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: Lisbon is calling: the BIO-Europe Startup Spotlight returns in March 2026BIO-Europe Spring 2026: partnership event brings funding hope to biotechsBIO-Europe partnering: Australian biotech companies share their experiences

Today, we welcome Dr Rosanne Dunn, Chief Scientific Officer and co-founder of HaemaLogiX, an Australian clinical-stage biotech company that's developing next-generation immunotherapies for multiple myeloma and other plasma cell disorders.HaemaLogiX is taking a precision approach by targeting novel antigens that are expressed exclusively on malignant plasma cells, sparing healthy ones. Recent peer-reviewed research has validated KMA and LMA as high-value targets, reinforcing the company's unique positioning in the field.Rosanne shares her journey from antibody engineering to building HaemaLogiX, the science behind their differentiated targets, the latest clinical and preclinical progress, and her perspectives on the future of immunotherapy for blood cancers as the company gears up for key milestones, including a planned IPO later this year.01:15 Meet Rosanne Dunn07:52 HaemalogiX's mission and novel antigens09:53 Overview of multiple myeloma and its symptoms12:19 Targeting malignant plasma cells while sparing normal ones19:25 Recent Peer-Reviewed Research26:08 Synergy with IMiDs like Revlimid29:08 Potential patient impact and quality of life35:05 Planned IPO in 2026 and funding needsInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: 5 cancers that immunotherapy can cureBIO-Europe partnering: Australian biotech companies share their experiencesHow are R&D Tax Incentives shaping Australia's biotech future?

Today we welcome Koenraad Wiedhaup, Co-Founder and CEO of Leyden Labs, and Clarissa Koch, the company's Chief Scientific Officer.Leyden Labs is pioneering a revolutionary non-vaccine approach to combat respiratory viruses like influenza and coronaviruses. Recently, they published groundbreaking data in Science Translational Medicine, demonstrating that their intranasal antibody spray is safe, well-tolerated, and delivers sustained protection right at the virus's entry point: the nose. This innovation addresses the shortcomings of traditional flu vaccines, which average just 13% effectiveness against infection and provide even less for vulnerable groups like the elderly and immunocompromised.We'll dive into the science, the company's journey since its 2020 founding, and their recent €50 million European funding boost amid U.S. biotech challenges.01:33: Meet Koenraad Wiedhaup03:13: Meet Clarissa Koch04:16: Leyden Labs' origin story06:21: Mucosal protection platform explained08:57: Complementing existing vaccines11:47: Science of mucosal immunity13:24: PanFlu lead candidate overview16:42: Key findings from recent publication22:02: Funding and future preparednessInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: Seven biotech companies to know in the NetherlandsThe Netherlands' biotech scene: The country sets its sights on becoming a global leader by 2040 Influenza solution deals pile up as pandemic preparedness increases 

Today, we welcome Janita Good, a Partner at Fieldfisher with nearly two decades of experience advising top organizations in pharmaceuticals, biotechnology, and medical devices. With a D.Phil. in Biochemistry from the University of Oxford, Janita brings a unique blend of scientific insight and legal expertise to her work on venture investments, joint ventures, partnerships, and M&A deals. She's advised on landmark transactions, including funding rounds for Phynova and MedAnnex, and collaborations like Intelligent Ultrasound's AI imaging partnerships.In this episode, Janita shares practical guidance for biotech leaders on timing partnerships with larger pharma companies, planning for commercialization from the start, balancing optimistic fundraising with realistic deal projections, and avoiding common legal pitfalls in M&A. We'll also look ahead to emerging trends in the sector and talk through the best way to structure a company for tax effective partnering and licensing.01:29: Meet Janita Good04:42: Fieldfisher's life sciences focus07:20: Fieldfisher's differentiated approach09:41: Timing early partnering discussions17:26: Structuring for efficient deals21:36: Planning commercialization from start25:22: Key early legal considerations30:00: Balancing fundraising and realism36:25: Optimism in the biotech industryInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: How biotech startups become unicornsThe ABC of biotech startup fundingBiotech's legal storm: Why securities class action lawsuits are surging

Today we're joined by Sean MacDonald, CEO of Kainova Therapeutics. With more than twenty years of biotech leadership and deep expertise in strategy and development, Sean is guiding the company through an exciting new chapter.We'll dive into Kainova's innovative GPCR-modulating platform, its promising pipeline, the science behind reversing tumor immunosuppression and targeting inflammation, and the reasons behind the recent rebrand from Domain Therapeutics to Kainova Therapeutics.We'll also be taking a look at the broader oncology landscape—what's hot, who's investing big, and where the biggest opportunities and challenges lie.01:09 – Meet Sean Macdonald05:40 – Kainova's GPCR platform and therapeutic focus08:57 – The story and meaning behind the Kainova rebrand10:25 – Series B funding and pipeline programs16:43 – Exciting trends and innovations in oncology29:17 – Upcoming milestones and future plansInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: GPCR therapies: Eight promising biotechs hacking the cell signaling pathwayEpisode 182: Building a smart oncology pipeline with Cumulus OncologyEpisode 34: eClinical Solutions, GPCR Therapeutics, Orbsen Therapeutics

Our guest is Sergey Jakimov, the Founding and Managing Partner of LongeVC, a venture capital firm dedicated to backing early-stage biotech and longevity startups. A serial entrepreneur, Sergey has co-founded ventures like Longenesis, a medical tech startup unlocking biomedical data for drug discovery, and the Longevity Science Foundation, a non-profit advancing healthy human lifespan. He's been named to Forbes Latvia's 30 Under 30 in technology and healthcare, and via LongeVC, he invests in innovation in areas including therapeutics, diagnostics, and personalized medicine.In this episode, Sergey warns about the rising danger of misinformation disguised as health advice—where influencers and hype outpace evidence-based science. I hope you enjoy our discussion as we unpack this public health challenge and explore solutions for a more credible biotech landscape.01:22           Meet Sergey Jakimov06:14           Developing a longevity focus10:47           A typical day at LongeVC13:26           The LongeVC portfolio17:28           Misinformation as health crisis26:04           The harm of bad advice33:16           The impact on biotech industry funding36:18           Strategies for addressing misinformation42:17           Optimism about trends in longevityInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: 13 anti-aging startups on a mission to extend livesTurning back time with cellular reprogramming: Shift raises $16 million in seed fundingAre European biotech VCs under pressure to scale? Time to get pragmatic 

Today, we're joined by Professor Matthew Wood, a leading figure in neuroscience and RNA-based therapeutics. He is Professor of Neuroscience at the University of Oxford, Deputy Head of the Medical Sciences Division, and Director of both the MDUK Oxford Neuromuscular Centre and the Oxford-Harrington Rare Disease Centre, a groundbreaking partnership between the University of Oxford and Harrington Discovery Institute dedicated to accelerating therapies for rare genetic diseases affecting millions worldwide.In today's episode we discuss his vision for making antisense oligonucleotides (or ASOs) and gene editing more modular, more scalable, and faster by collaborating with regulators, scientists, and patient groups to bring hope to those with rare neuromuscular and genetic conditions.With rare disease day coming up just next week, I hope you enjoy the insights that Professor Wood shares on the future of the fight against rare disease.01:23 – Meet Matthew Wood07:26 – The Oxford-Harrington Rare Disease Centre10:33 – Collaborations, philanthropy, and industry partnerships13:55 – Key challenges in rare disease therapy development20:00 – Modular and scalable platforms for ASOs28:08 – Scaling gene editing like CRISPR for rare diseases32:38 – Role of AI and computational tools in acceleration37:28 – Future breakthroughs in rare disease treatments44:07 – Advice for new researchers in the fieldInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: Prader Willi syndrome: five much-anticipated therapies poised for approval First-ever approval for Barth Syndrome treatment: what does this mean for ultra-rare disease therapeutics? When rare diseases are not so rare after all: A closer look at where and why this happens

As we mark the International Day of Women and Girls in Science, we welcome Avital Sharir-Ivry, Co-Founder and Chief Scientific Officer of ProPhet, an innovative Israeli startup launched in late 2024 from the AION Labs venture studio.With a PhD in computational biology and drug research, Avital brings deep expertise in structural biology, enzyme design, and evolutionary bioinformatics to her role leading ProPhet's scientific efforts.ProPhet itself is changing small molecule drug discovery by using advanced AI and machine learning to map proteins and compounds into a shared interaction space. This enables rapid, scalable screening of billions of molecules—even for so-called "undruggable" targets—without relying on solved structures or massive datasets, speeding up hit-finding and expanding the reachable therapeutic landscape.01:36 Meet Avital Sharir-Ivry08:55 How ProPhet emerged from AION Labs challenge12:12 Core AI technology for hit-finding at scale15:00 Benchmarks and collaborations17:54 ProPhet's differentiation from traditional drug discovery19:45 Importance of scaling small molecule exploration24:19 Pharma AI investments and emerging trends26:11 Future AI breakthroughs in drug discovery27:04 Challenges and progress for women in science31:15 Keep up with ProPhetInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: Seven influential women in biotech in 2026 Report: Adopting AI in biologics discoveryWebinar: How AI and LLMs are helping chemists design drugs faster and smarter 

Today, we're joined by Thomas Hopkins, Vice President and Head of ExploR&D at Eli Lilly. With a background as a physician-scientist in oncology, Thomas has spent his career bridging bold discovery science with rigorous development, first in academia and clinical practice, then at Lilly since 2015.Lilly ExploR&D represents new thinking in the pharma-biotech collaboration model: a shared-risk, deep scientific partnership designed specifically for early-stage biotechs. It provides full-stack R&D capabilities helping companies overcome the toughest hurdles in moving from molecule creation to clinical proof-of-concept, all while staying lean in a challenging funding environment.In this episode, Thomas dives into his journey shaping ExploR&D, how the program works in practice, current priorities in modalities and therapeutic areas, and offers some practical advice for biotechs seeking to partner with Eli Lilly.01:30 — Meet Tom Hopkins05:11 — What makes ExploR&D biotech-friendly07:46 — How collaborations work in practice09:40 — Shared risk models14:25 — Engaging bold science early28:16 — Success stories and advice for biotechsInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: Eli Lilly's strategy in motion: Beyond diabetes and obesityOver $3 billion in a month: Why is Eli Lilly starting 2025 on a buying spree?What to look for in a biotech incubator

Today, my guest is Dr. Clare Wareing, Founder and CEO of Cumulus Oncology, who joins us from Edinburgh. With over 25 years of expertise in oncology drug development, Clare has built a remarkable career translating scientific breakthroughs into life-changing therapies. Cumulus Oncology is curating a risk-adjusted portfolio of preclinical assets focused on high unmet needs in oncology. Their platform-agnostic, approach prioritizes patient subgroups and precision medicine to boost success rates and drive value creation.In this conversation, we explore Clare's journey to and through biotech, Cumulus and the current state of oncology in biotech, the vibrant Scottish biotech ecosystem, and her vision for the future for 2026 and beyond.01:17: Meet Clare Wareing03:57: Inspiration for founding Cumulus Oncology.05:38: Cumulus's unique drug development model.09:53: Overview of Cumulus's asset portfolio.13:05: Importance of the patient subgroup strategy.17:41: Trends in oncology drug discovery.21:09: Drivers of oncology deal-making activity.24:22: Challenges in accessing venture capital.30:06: Future milestones for Cumulus Oncology.Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: Curing cancer: Daiichi Sankyo's ambitious ADC approachCracking Cancer's Code: Transforming Research with Novel Cancer ModelsNew cancer cell discovery sheds light on childhood blood cancer

Today, we're thrilled to have Tim Opler, a leading voice in biotech investment banking. Tim's career spans academia, Credit Suisse, and co-founding Torreya Partners, which Stifel acquired in 2023. As Managing Director in Stifel's Global Healthcare Group, he's advised on over 150 deals totaling more than $100 billion, shaping major M&A, licensing, and financings in life sciences.Tim is renowned for his insightful Biopharma Market Updates, and in this episode, we'll dive into his December 2025 edition, where he outlines five transformative trends set to drive biopharma for the next decade: M&A booms, giant markets like obesity and aging drugs, China's rising innovation, AI's reshape of healthcare, and incredible scientific advances.01:22 - Meet Tim Opler03:12 - Stifel and the Biopharma Market Updates05:50 - Trend 1: M&A Booms10:06 - Trend 2: Giant Markets17:05 - Trend 3: China's Innovation22:29 - Trend 4: AI Reshaping Healthcare28:42 - Trend 5: Incredible Science34:18 - Looking forwardInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: 10 biotech companies in China you should know aboutWhen AI isn't enough: How physics is shaping the next wave of drug discovery JPM 2026: what's the outlook like this year? 

Today I'm joined by not one, not two, but three guests with their takes on the biotech year ahead. In December we tasked Labiotech journalists Jules Adam, Roohi Peter, and Willow Shah-Neville with the task of identifying the five biotech players that they thought would be the ones to watch in 2026. Now you can read that article at Labiotech-dot-EU, and we've linked it in the show notes here in your podcast player, too, but on today's episode I'm joined by Jules, Roohi, and Willow who explain a little more about the companies that caught their eye and what might be expected of those companies in the year ahead.15 companies, three journalists, all in one special podcast as we uncover the companies to watch in 2026.1:18     Meet Jules Adam2:30     Abivax4:04     AAVantgarde Bio6:10     Isotope Technologies Munich (ITM)8:16     MaaT Pharma9:55     Novo Nordisk13:15    Meet Willow Shah-Neville14:29    Kardigan18:23    Braveheart Bio21:16    Beam Therapeutics24:34    MindMed27:39    Kailera Therapeutics32:36    Meet Roohi Peter33:30    Aspen Neuroscience34:45    Reunion Neuroscience36:14    MapLight Therapeutiucs37:41    Hope Medicine38:59    RegenxbioInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: Keep an eye on these 15 biotech companies in 2026 Biotech in 2025: A retrospective Eight of the biggest immunology and inflammation (I&I) deals in 2025

Welcome to our first episode for 2026.Today, we're joined by Hakan Goker, Managing Director at M Ventures, the strategic corporate venture capital arm of Merck KGaA. With over two decades in biotech investing, Hakan has driven transformative deals in oncology, autoimmune diseases, and beyond, including standout 2025 investments like FoRx Therapeutics and portfolio milestones such as Artios' FDA Fast Track designation. As we kick off 2026 at Beyond Biotech, Hakan shares insights on corporate VC advantages, emerging therapeutic priorities, and the industry's evolving landscape amid rising M&A and AI innovation. 1:10                 Meet Hakan Goka4:37                 About M Ventures and pharma CVC8:14                 Sourcing innovative biotechs12:52                How M Ventures works with Merck KGaA16:54              M Ventures in 202524:46                Areas to watch in the new year29:19                Looking forward to 202632:20                The next big thing in biotech?33:08                Advice for biotechs pitching CVCInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: The ABC of biotech startup fundingSeven genome sequencing companies to look out forLabiotech's 2025 biotech funding tracker

Welcome to our final episode for 2025. We're taking a little break for the holidays but we'll be back again on Friday 9th of January to kick off our year with the Managing Director of Merck KGaA's M Ventures, Hakan Goker.Today, though, I'm joined by Ester in t'Groen of Johnson & Johnson.Fresh off the American Society of Hematology (ASH) Annual Meeting in Orlando, where J&J presented over 60 abstracts, Ester shares insights into the company's portfolio and the advances that the company has made over recent years in the hematology space.She walks us through the real-world evidence for some pretty significant results from the thousands of patients in their clinical trials, and explain what's next for J&J in hematology in 2026—including some exciting readouts.01:14 - Meet Ester in t'Groen    02:37 - Winning the Kilmer Medal06:32 - J&J's key focus areas07:32 - The hematology portfolio19:07 - All about ASH 202523:49 - The MajesTEC-3 data27:43 - The value of real-world datasets32:06 - Looking forward into 2026Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: Blood Cancer Awareness Month: What biotech holds in store 10 oncology deals in 2025 spotlight where industry leaders are betting bigT cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

In this episode we sit down with Martin Beck, Senior Vice President and Head of the Inflammation Business Unit at Boehringer Ingelheim. Martin grew up just down the road from the company's headquarters in Germany, joined as a scholarship student more than 20 years ago, and never really left – and you'll hear why he still loves it.We spend most of the episode focused on a disease that doesn't get nearly enough attention: idiopathic and progressive pulmonary fibrosis. These are rare, fatal lung-scarring conditions that kill faster than many cancers, yet patients often shrug off the first symptoms as “just aging.” Martin walks us through why half the people on today's treatments stop taking them, how BI just brought the first new medicine in over a decade to the U.S. market, and why an AI tool that spots microscopic changes on lung scans might finally help doctors diagnose and treat these patients' years earlier. 01:24   Meet Martin Beck04:21   About Boehringer Ingelheim07:12   Understanding idiopathic & progressive pulmonary fibrosis10:16   Current treatments & high discontinuation rates12:25   BI's long-term investment in PF16:02   eLung AI tool for earlier diagnosis22:16   A new oral PDE4B inhibitor28:13   Key data highlights from the recent ERS congress30:31   FDA approval & global rollout plansInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: Idiopathic pulmonary fibrosis: Refoxy, Boehringer, Insilico, and more on the hunt for curative treatmentsEight respiratory disease companies advancing innovative therapies in 2025BI: Life with pulmonary fibrosis 

Daiichi Sankyo has been pioneering ADCs since 2010, with a pipeline targeting over 30 indications and potentially reaching 400,000 patients.In today's episode I'm joined by Dr. Markus Kosch, Head of the EU Oncology Business Division at Daiichi Sankyo. A physician by training with a deep academic background in oncology, Markus has spent over two decades advancing cancer care, from clinical practice to leadership roles shaping strategy across Europe and Canada. Since joining Daiichi Sankyo in 2021, he has been at the forefront of one of the industry's most ambitious ADC pipelines, overseeing more than 60 clinical trials across 24 countries and driving landmark approvals that are redefining treatment in breast, lung, and gastric cancers.This week's episode is brought to you with the support of Kadans. Looking for the perfect space to grow your Life Sciences company? Kadans Science Partner is Europe's leading provider of cutting-edge lab and offices spaces, tailored to your needs. Kadans puts you at the centre of innovation, giving you the chance to connect with top researchers, universities, and investors through its international network. Here, you'll join a vibrant community of innovators driving real change. Are you ready to take your research to the next level? Learn more at kadans.com – where innovation thrives. 01:45.         Meet Markus Kosch03:12.         Clinical background shaping an industry role04:46.         Daiichi Sankyo's 40-year oncology legacy06:19.         European investments and Munich hub10:34.         ADC platform strengths explained14:20.         Key ESMO 2025 trial dataClarification: The reference to ‘TB01' at 16:24 refers to the TROPION-Breast02 clinical trial, not TB01.19:43.         Managing risks and partnerships23:35.         Patient advocacy in trial design33:59.         Future of oncology and ADCsInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: 10 oncology deals in 2025 spotlight where industry leaders are betting bigAstraZeneca and Daiichi Sankyo's Enhertu recommended for approvalTen drugs to watch in 2025: will these therapies become blockbusters?

Send us a textDee and Carol talk about flowers and veggies with 'viridis' as the species name, plus a book on houseplant propagation, and more.For all the details, check out our newsletterTo watch this episode on YouTube: click hereInsect of the Week: Paper WaspsFlowers:Ephedra viridis - Morman Tea Helleborus viridis - Green HelleboreAsclepias viridis - Green Milkweed Crataegus viridis - Green HawthornAcer palmatum ‘Viridis.'Vegetables:Collard Greens - Brassica oleracea var. viridis Callaloo - Amaranthus viridisCucumber Viridis F1 On the Bookshelf:The Ultimate Guide to Houseplant Propagation: Step-by-step techniques for making more houseplants… for free! By Lindsay Sisti from @alltheplantbabies on Instagram (Amazon Link)Dirt:Why do ginkgo trees lose their leaves all at once? On InstagramRabbit Holes:Dee: Where does rose oil come from? An article, an Instagram link, and an article about how it's used!Carol: The Unselected Journals of Emma M. Lion, Volume 3 by Beth Brower, and The Killer Question by Janice Hallett. Check out our affiliate links here.Support the showOn Instagram: Carol: Indygardener, Dee: RedDirtRamblings, Our podcast: TheGardenangelists.On Facebook: The Gardenangelists' Garden Club.On YouTube.

Two weeks ago, the biopharma industry gathered in Vienna, Austria, for BIO-Europe. Tens of thousands of one-on-one meetings were organized between innovators and out-licensors with top pharma companies and venture capitalists eager to partner and invest. For the large pharma firms, it's a chance to learn about new science and keep tabs on evolving assets. For smaller biotechs, though, it can be three-days of high-pressure networking where a lot is riding on making the right pitch to the right company at just the right time. Get it right, and you walk away with a clear path forward and the cash to fund it. But get unlucky and you might find yourself with few options in the New Year.This year, we decided to follow one biotech heading into their first BIO-Europe partnering conference. We met with DISCO Pharma three times over the last month to follow their BIO-Europe journey:Before the event to learn about the science behind DISCO and understand what their goals were heading into BIO-Europe. At the event itself to talk about how the partnering meetings had been going and how the event had shaped up for DISCO. A week after BIO-Europe had closed, diving into the follow-up activities and learning about the next steps for this German biotech.I hope you enjoy my conversations with Ajla Hrle, Chief Business Officer at DISCO, and this behind the scenes look at BIO-Europe from an innovator's perspective.02:25          Preparing for BIO-Europe16:51           On the floor at BIO-Europe22:23          Following up from BIO-EuropeInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: BIO-Europe partnering: Australian biotech companies share their experiencesPractical partnering at BIOSPAIN: on the ground with biotech innovators ready to take the next stepBiotech in Vienna: a budding life science hub 

Last week saw more than 5,900 people from 3,200 companies gather in Vienna, Austria, for the continent's largest biopharma partnering conference, BIO-Europe. Over three days the world's top pharma companies, most innovative biotechs, and life science professionals from 60 countries took more than 32,000 one-on-one meetings, made the connections, and sealed deals that will drive the industry forward into 2026 and beyond.Among the highlights of BIO-Europe this year was the Startup Spotlight contest. This exciting competition offers biotech entrepreneurs an affordable opportunity to engage with top-tier investors and other important players in the biotech industry and to take their business to the next level. Eight finalists made their pitches at BIO Europe and one, Fusix Biotech from Germany, came out on top.This week on Beyond Biotech I'm joined by Fusix Biotech's Managing Director and co-founder, Jennifer Altomonte, who tells me about her journey through the industry, Fusix's InFUSE platform, and what it's like to pitch – and win – one of the most important biopharma startup competitions of the year.01:34               Meet Jennifer Altomonte05:12               Co-founding Fusix Biotech10:37               Fusix Biotech and the InFUSE platform18:50               Intellectual property for a young company20:04               The BIO-Europe Startup Spotlight23:47               The impact of the competition win29:05               The milestones ahead30:33               What does a successful 2026 look like for Fusix Biotech?31:56               Learn more about Fusix BiotechThis episode is supported by EBD Group.Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: BIO-Europe partnering: Australian biotech companies share their experiencesFour New Technologies That Will Change Cancer TreatmentWhy is the immunology and inflammation market suddenly attracting a wave of investment?

We're so excited to share this riveting dive into the magic and mystery of tarot with tarot expert Beth Owl's Daughter. In this episode we discuss the spirit of tarot, court cards, reversals, and the ethics of doing readings plus how to know when you're ready to start doing your own readings. For more information on Beth and her work, check out owlsdaughter.comTo sign up for her newsletter (featuring Card of the Week every Monday, plus other tidbits): https://www.owlsdaughter.com/stay-in-touch/#newsletterTo schedule a personal reading: https://www.tickettailor.com/events/bethowlsdaughter/1726070To join her free monthly online Tarot study & friendship group (all levels welcome): https://app.groups.place/group/triangletarotFor her Card of the Week: https://www.owlsdaughter.com/weekly-tarotFind Beth's Blog articles featuring seasonal lore, etc.: https://www.owlsdaughter.com/blogFor more information on us, check out our websites: debbowen.com and samanthafey.com.You can also find Samantha on Instagram @samanthaofey.    If you want to pre-order Deb's book, go to debbowen.com or (if outside the US), check out clairegelder.com  Signed copies of Samantha's book Heavenly Alliance and The Awake Dreamer are available at samanthafey.com.  Be sure to check out Samantha's other podcast Enlightened Empaths.    Have a great week. Be the Light!  

Blaine begins the episode with a podcast overview and the generalities of this week's episode (0:02). Once Donovan joins, they discuss the return of the longest-running TV show, 'It's Always Sunny In Philadephia' and determine how its sustained its longevity (3:15). From there, they have brief discussion on the Apple TV+ series 'Stick' and its most recent episode (11:14). To conclude the non-spoiler segment, they give thought to 'The Bear' as a whole season (14:42). After a short break, it's time to discuss the ridiculous plot points of both 'It's Always Sunny In Philadelphia' and 'Abbott Elementary,' as the gang end their time there (14:57). Both hosts agree that the Apple TV+ 'Stick' had its best episode thus far, and they explain why (32:38). Finally, it's the last four episodes of the fourth season of 'The Bear' (35:38) Was it better than season three? Were problems solved? All that, and more on this week's Taking It Down episode. For more, visit the link that's provided here to go to The Alabama Take: https://thealabamatake.com/If you wish to sign up for the newsletter mentioned, use this link to sign up and have it delivered to your inbox: https://thealabamatake.com/newsletterTo help the podcast and The Alabama Take website, visit the link here: https://buymeacoffee.com/thealabamatake

We hope you've enjoyed this journey of the first season of The Karen Kingsbury Show! Today's episode is the final episode and a very special one as Karen talks with Tyler Russell about his very serious decision to co-write and direct Someone Like You. Tyler shares the moment when he knew, there was no turning back!Karen Kingsbury has told a million stories, but this is the first time she's told HER story!  Out of all of her bestsellers, Karen wants to be remembered for the stories she wrote with the days of her life! On her first ever podcast, Karen hopes and prays throughout these episodes you'll see yourself in the stories she shares.Thanks for listening and sharing this episode with a friend!SHOW LINKS:For tickets and more information about Karen's movie SOMEONE LIKE YOU, visit SomeoneLikeYou.movie.Click here to view the trailer for SOMEONE LIKE YOU movieFor information about Karen's books, visit KarenKingsbury.comTo sign up for Karen's Newsletter, visit KarenKingsbury.com/newsletterTo receive information about an adoption grant, visit KarenKingsbury.com/foundationRead by Ryan Grow.  Personal ad for Someone like you.Check out Someone Like You, a new film from Karen Kingsbury.You can also watch this episode on YouTube HERE.The Great American Family NetworkUnsung Hero MovieThe Candace Cameron Bure PodcastCheck out Someone Like You, a new film from Karen Kingsbury.You can also watch this episode on YouTube HERE. Check out Someone Like You, a new film from Karen Kingsbury.You can also watch this episode on YouTube HERE. You can also watch this episode on YouTube HERE.

Someone Like You is out in theaters! Over this past season you've gone through the journey of Karen's life and how it's come to producing her very own movie! Now you can catch that movie on the big screen! On today's episode Karen talks with the stars of Someone Like You, Jake Allyn and Sarah Fisher, and listen closely, because Karen may even share a secret!Karen Kingsbury has told a million stories, but this is the first time she's told HER story!  Out of all of her bestsellers, Karen wants to be remembered for the stories she wrote with the days of her life! On her first ever podcast, Karen hopes and prays throughout these episodes you'll see yourself in the stories she shares. Thanks for listening and sharing this episode with a friend! SHOW LINKS:For tickets and more information about Karen's movie SOMEONE LIKE YOU, visit SomeoneLikeYou.movie.Click here to view the trailer for SOMEONE LIKE YOU movieFor information about Karen's books, visit KarenKingsbury.comTo sign up for Karen's Newsletter, visit KarenKingsbury.com/newsletterTo receive information about an adoption grant, visit KarenKingsbury.com/foundationRead by Ryan Grow.  Personal ad for Someone like you.Check out Someone Like You, a new film from Karen Kingsbury.You can also watch this episode on YouTube HERE.The Great American Family NetworkUnsung Hero MovieThe Candace Cameron Bure PodcastCheck out Someone Like You, a new film from Karen Kingsbury.Check out Someone Like You, a new film from Karen Kingsbury.You can also watch this episode on YouTube HERE. You can also watch this episode on YouTube HERE.

Karen shares the deeply personal moment when her husband suggested they sell everything ... if that's what it took to follow God's will.Karen Kingsbury has told a million stories, but this is the first time she's told HER story!  Out of all of her bestsellers, Karen wants to be remembered for the stories she wrote with the days of her life! On her first ever podcast, Karen hopes and prays throughout these episodes you'll see yourself in the stories she shares.Thanks for listening and sharing this episode with a friend! SHOW LINKS:For tickets and more information about Karen's movie SOMEONE LIKE YOU, visit SomeoneLikeYou.movie.Click here to view the trailer for SOMEONE LIKE YOU movieFor information about Karen's books, visit KarenKingsbury.comTo sign up for Karen's Newsletter, visit KarenKingsbury.com/newsletterTo receive information about an adoption grant, visit KarenKingsbury.com/foundationRead by Ryan Grow.  Personal ad for Someone like you.Check out Someone Like You, a new film from Karen Kingsbury.You can also watch this episode on YouTube HERE.The Great American Family NetworkUnsung Hero MovieThe Candace Cameron Bure PodcastCheck out Someone Like You, a new film from Karen Kingsbury.Check out Someone Like You, a new film from Karen Kingsbury.You can also watch this episode on YouTube HERE. You can also watch this episode on YouTube HERE.

Welcome back to another great episode of The Saren Kingsbury Show. On today's show, Karen talks with Tay Lautner about their Lemons Foundation and the importance of mental health. Karen Kingsbury has told a million stories, but this is the first time she's told HER story!  Out of all of her bestsellers, Karen wants to be remembered for the stories she wrote with the days of her life! On her first ever podcast, Karen hopes and prays throughout these episodes you'll see yourself in the stories she shares.Thanks for listening and sharing this episode with a friend!Show Links:For tickets and more information about Karen's movie SOMEONE LIKE YOU, visit SomeoneLikeYou.movie.Click here to view the trailer for SOMEONE LIKE YOU movieFor information about Karen's books, visit KarenKingsbury.comTo sign up for Karen's Newsletter, visit KarenKingsbury.com/newsletterTo receive information about an adoption grant, visit KarenKingsbury.com/foundationRead by Ryan Grow.  Personal ad for Someone like you.Check out Someone Like You, a new film from Karen Kingsbury.You can also watch this episode on YouTube HERE.The Great American Family NetworkUnsung Hero MovieThe Candace Cameron Bure PodcastCheck out Someone Like You, a new film from Karen Kingsbury.You can also watch this episode on YouTube HERE. Lemons by TaySqueeze Podcast Connect with Tay Lautner Suicide Hotline Check out Someone Like You, a new film from Karen Kingsbury.You can also watch this episode on YouTube HERE. You can also watch this episode on YouTube HERE.

On today's show Karen Kingsbury talks with her dear friend Shelene Bryan about finding a reason to laugh. Whether you're on a cruise or in a prison, Shelene reminds all of us there's laughter everywhere!  Karen Kingsbury has told a million stories, but this is the first time she's told HER story!  Out of all of her bestsellers, Karen wants to be remembered for the stories she wrote with the days of her life! On her first ever podcast, Karen hopes and prays throughout these episodes you'll see yourself in the stories she shares.  Thanks for listening and sharing this episode with a friend!Show Links:For tickets and more information about Karen's movie SOMEONE LIKE YOU, visit SomeoneLikeYou.movie.Click here to view the trailer for SOMEONE LIKE YOU movieFor information about Karen's books, visit KarenKingsbury.comTo sign up for Karen's Newsletter, visit KarenKingsbury.com/newsletterTo receive information about an adoption grant, visit KarenKingsbury.com/foundationRead by Ryan Grow.  Personal ad for Someone like you.Check out Someone Like You, a new film from Karen Kingsbury.You can also watch this episode on YouTube HERE.The Great American Family NetworkUnsung Hero MovieThe Candace Cameron Bure PodcastCheck out Someone Like You, a new film from Karen Kingsbury.You can also watch this episode on YouTube HERE. Check out Someone Like You, a new film from Karen Kingsbury.You can also watch this episode on YouTube HERE. You can also watch this episode on YouTube HERE.

In Episode 11 of The Karen Kingsbury Show, Karen talks with her daughter Kelsey about one of the mottos their family lives by: look for the miracles in life. From an officer that may have been an angel, to Rod Stewart and the High Line Park, Kelsey and Karen share the many memories they have of witnessing miracles. Karen Kingsbury has told a million stories, but this is the first time she's told HER story!  Out of all of her bestsellers, Karen wants to be remembered for the stories she wrote with the days of her life! On her first ever podcast, Karen hopes and prays throughout these episodes you'll see yourself in the stories she shares.Thanks for listening and sharing this episode with a friend!Show Links:For tickets and more information about Karen's movie SOMEONE LIKE YOU, visit SomeoneLikeYou.movie.Click here to view the trailer for SOMEONE LIKE YOU movieFor information about Karen's books, visit KarenKingsbury.comTo sign up for Karen's Newsletter, visit KarenKingsbury.com/newsletterTo receive information about an adoption grant, visit KarenKingsbury.com/foundationRead by Ryan Grow.  Personal ad for Someone like you.Check out Someone Like You, a new film from Karen Kingsbury.You can also watch this episode on YouTube HERE.The Great American Family NetworkUnsung Hero MovieThe Candace Cameron Bure PodcastCheck out Someone Like You, a new film from Karen Kingsbury.You can also watch this episode on YouTube HERE. Check out Someone Like You, a new film from Karen Kingsbury.You can also watch this episode on YouTube HERE. You can also watch this episode on YouTube HERE.

The mother daughter dynamic is so beautiful, and yet every mother and daughter knows that it can also be complex. On today's show Karen and her daughter Kelsey join friends and mother daughter duo Candace and Natasha Bure to talk about this relationship. Cameron and Karen share their experience of raising strong daughters and Natasha and Kelsey share what it was like growing up with parents in the spotlight. Karen Kingsbury has told a million stories, but this is the first time she's told HER story!  Out of all of her bestsellers, Karen wants to be remembered for the stories she wrote with the days of her life! On her first ever podcast, Karen hopes and prays throughout these episodes you'll see yourself in the stories she shares.Thanks for listening and sharing this episode with a friend!Show Links:For tickets and more information about Karen's movie SOMEONE LIKE YOU, visit SomeoneLikeYou.movie.Click here to view the trailer for SOMEONE LIKE YOU movieFor information about Karen's books, visit KarenKingsbury.comTo sign up for Karen's Newsletter, visit KarenKingsbury.com/newsletterTo receive information about an adoption grant, visit KarenKingsbury.com/foundation Read by Ryan Grow.  Personal ad for Someone like you.Check out Someone Like You, a new film from Karen Kingsbury.You can also watch this episode on YouTube HERE.The Great American Family NetworkUnsung Hero MovieThe Candace Cameron Bure PodcastCheck out Someone Like You, a new film from Karen Kingsbury.You can also watch this episode on YouTube HERE. You can also watch this episode on YouTube HERE.

This week: Jen answers questions from Patreon subscribers about: her second tattoo, being on a TV game show, writing for TV, how to be in a relationship with an ADHD-er and more! Sign up for a 7-day free trial of Patreon and get full length, ad-free episodes: https://tinyurl.com/ycy3jrkxTo listen to Q&A WITH JK PART 1 go here: https://tinyurl.com/dnjfuwwk Learn How To Change Your Patreon Tier here: https://tinyurl.com/2juefh7f Get “Your Women Are Literally Humans Tank Tops” here: https://tinyurl.com/yc6scbh3To join Jen's free newsletter go here: http://www.jenkirkman.com/newsletterTo stream or buy Jen's last comedy album (2022) “OK, GEN-X” go here: https://800PGR.lnk.to/OKGenXINTo buy Jen a coffee go here: https://www.buymeacoffee.com/JenkirkmanSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This week: Jen talks about the right way to put sprinkles on ice cream, the night she and Winona Ryder hung out, Jen's parents want to party with her friends, killing spotted lantern flies in NYC, AI therapists are not helpful, and the Godfather of AI quit his job at Google to warn the world about killer robots.Sign up for a 7-day free trial of Patreon and get full length, ad-free episodes: https://tinyurl.com/ycy3jrkxLearn How To Change Your Patreon Tier here: https://tinyurl.com/2juefh7f Get “Your Women Are Literally Humans Tank Tops” here: https://tinyurl.com/yc6scbh3To join Jen's free newsletter go here: http://www.jenkirkman.com/newsletterTo stream or buy Jen's last comedy album (2022) “OK, GEN-X” go here: https://800PGR.lnk.to/OKGenXINTo buy Jen a coffee go here: https://www.buymeacoffee.com/JenkirkmanSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This week: Jen talks about a very chatty customer service phone operator for Jet Blue, being afraid of the woods at night, debunking government conspiracy alien craft crash theories, and the Next Door app'ers are freaking out over a creepy van in the neighborhood.Sign up for a 7-day free trial of Patreon and get full length, ad-free episodes: https://tinyurl.com/ycy3jrkxLearn How To Change Your Patreon Tier here: https://tinyurl.com/2juefh7f Get “Your Women Are Literally Humans Tank Tops” here: https://tinyurl.com/yc6scbh3Get Your “Women Are Literally Humans Tote Bag” here: https://tinyurl.com/7ks38e65 To join Jen's free newsletter go here: http://www.jenkirkman.com/newsletterTo stream or buy Jen's last comedy album (2022) “OK, GEN-X” go here: https://800PGR.lnk.to/OKGenXINTo buy Jen a coffee go here: https://www.buymeacoffee.com/JenkirkmanSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This week: Jen talks about the excitement of the SAG-AFTRA Union joining the WGA on strike, Jen's parents are pro Matt Damon and anti-billionaire, the downfall of Jonah Hill as a mental health role model, Jen is worried that Madonna is secretly on drugs, and an apology for suggesting going to Target on a first date. Sign up for a 7-day free trial of Patreon and get full length, ad-free episodes: https://tinyurl.com/ycy3jrkxLearn How To Change Your Patreon Tier here: https://tinyurl.com/2juefh7f Get “Your Women Are Literally Humans Tank Tops” here: https://tinyurl.com/yc6scbh3Get Your “Women Are Literally Humans Tote Bag” here: https://tinyurl.com/7ks38e65 To join Jen's free newsletter go here: http://www.jenkirkman.com/newsletterTo stream or buy Jen's last comedy album (2022) “OK, GEN-X” go here: https://800PGR.lnk.to/OKGenXINTo buy Jen a coffee go here: https://www.buymeacoffee.com/JenkirkmanSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

SEASON 11: EPISODE 26: SHIPSRELEASE DATE 7/13/2023This week: Jen reads a thread on the Next Door app about a couple who were appalled that teenaged boys threw eggs at them. Jen goes to a crappy Titanic exhibit in NYC, the problem with billionaires and dangerous expeditions, and Elon wants childless people to lose the right to vote. Sign up for a 7-day free trial of Patreon and get full length, ad-free episodes: https://tinyurl.com/ycy3jrkxLearn How To Change Your Patreon Tier here: https://tinyurl.com/2juefh7f Get “Your Women Are Literally Humans Tank Tops” here: https://tinyurl.com/yc6scbh3Get Your “Women Are Literally Humans Tote Bag” here: https://tinyurl.com/7ks38e65 To join Jen's free newsletter go here: http://www.jenkirkman.com/newsletterTo stream or buy Jen's last comedy album (2022) “OK, GEN-X” go here: https://800PGR.lnk.to/OKGenXINTo buy Jen a coffee go here: https://www.buymeacoffee.com/JenkirkmanSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This week: Jen is very scattered but manages to talk about her addiction and then crash watching Married At First Sight when she was sick for a week, great advice on the futility of time management from a book Jen read, a heart-warming ADHD tale of my bonding with a stranger, and there's more drama happening on the Next Door App! Sign up for a 7-day free trial of Patreon and get full length, ad-free episodes: https://tinyurl.com/ycy3jrkxLearn How To Change Your Patreon Tier here: https://tinyurl.com/2juefh7f Get “Your Women Are Literally Humans Tank Tops” here: https://tinyurl.com/yc6scbh3Get Your “Women Are Literally Humans Tote Bag” here: https://tinyurl.com/7ks38e65 To join Jen's free newsletter go here: http://www.jenkirkman.com/newsletterTo stream or buy Jen's last comedy album (2022) “OK, GEN-X” go here: https://800PGR.lnk.to/OKGenXINTo buy Jen a coffee go here: https://www.buymeacoffee.com/JenkirkmanSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This week: Jen talks about whistleblower David Grush testifying that there is a secret government committee that has recovered “non-human” spacecraft, nobody is afraid of aliens, the Gen-Z trend of “bed-rotting” which Jen calls “Bedquarters”, a Rona rebound, someone on the Next Door App wants to sue Jen for slander and more! Sign up for a 7-day free trial of Patreon and get full length, ad-free episodes: patreon.com/jenkirkmanLearn How To Change Your Patreon Tier here: https://tinyurl.com/2juefh7f Get “Your Women Are Literally Humans Tank Tops” here: https://tinyurl.com/yc6scbh3Get Your “Women Are Literally Humans Tote Bag” here: https://tinyurl.com/7ks38e65 To join Jen's free newsletter go here: http://www.jenkirkman.com/newsletterTo stream or buy Jen's last comedy album (2022) “OK, GEN-X” go here: https://800PGR.lnk.to/OKGenXINTo buy Jen a coffee go here: https://www.buymeacoffee.com/JenkirkmanSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This week: Jen talks about Kim Cattrall's upcoming cameo on “And Just Like That” and the annoying line from Carrie in the trailer about using the stove for shoes. Also Jen talks about getting the Coco after 3 1/2 years of outrunning it, Al Pacino and Robert DeNiro are insane for having kids at age 80, and Jen continues to troll people on the Next Door App. Sign up for a 7-day free trial of Patreon and get full length, ad-free episodes: patreon.com/jenkirkmanLearn How To Change Your Patreon Tier here: https://tinyurl.com/2juefh7f Get “Your Women Are Literally Humans Tank Tops” here: https://tinyurl.com/yc6scbh3Get Your “Women Are Literally Humans Tote Bag” here: https://tinyurl.com/7ks38e65 To join Jen's free newsletter go here: http://www.jenkirkman.com/newsletterTo stream or buy Jen's last comedy album (2022) “OK, GEN-X” go here: https://800PGR.lnk.to/OKGenXINTo buy Jen a coffee go here: https://www.buymeacoffee.com/JenkirkmanSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This week: Jen reads and gives her commentary on Jack Smith's indictment of Donald Trump for having boxes of classified info at Mar-A-Lago, Seth Rogan is a child-free hero, not having kids isn't interesting to talk about - why do people care, the time Francis Bean Cobain told Jen she liked her comedy, Jen's parents won't make a will, and what “Women are Literally Humans” means. Sign up for a 7-day free trial of Patreon and get full length, ad-free episodes: patreon.com/jenkirkmanLearn How To Change Your Patreon Tier here: https://tinyurl.com/2juefh7f Read Jack Smith's Trump Indictment Pages here: https://tinyurl.com/4kr6kfxwGet “Your Women Are Literally Humans Tank Tops” here: https://tinyurl.com/yc6scbh3Get Your “Women Are Literally Humans Tote Bag” here: https://tinyurl.com/7ks38e65 To join Jen's free newsletter go here: http://www.jenkirkman.com/newsletterTo stream or buy Jen's last comedy album (2022) “OK, GEN-X” go here: https://800PGR.lnk.to/OKGenXINTo buy Jen a coffee go here: https://www.buymeacoffee.com/JenkirkmanSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Jen talks about how her podiatrist thought Jen was upset because she is “old”, making new friends as an adult, coping with a fear of building heights and elevators with Klonopin and oversharing, watching The Notebook for the first time last week and more random ADHD rambling! Go to Patreon to hear this episode in it's entirety (60-90 minutes) and without ads: patreon.com/jenkirkmanTo shop Jen's merchandise store go here: http://jenkirkman.merchcentral.comTo stream or buy Jen's last comedy album (2022) “OK, GEN-X” go here: https://800PGR.lnk.to/OKGenXINTo join Jen's free newsletter go here: http://www.jenkirkman.com/newsletterTo buy Jen a coffee go here: https://www.buymeacoffee.com/JenkirkmanSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This week: THE FULL EPISODE 7, SEASON 11 FROM 2/15/23 TITLED “THERAPY” IS NOW UNLOCKED AND AVAILABLE TO THE PUBLIC. ALL NO FUN EPISODES CAN ONLY BE HEARD AD-FREE AND IN FULL ON PATREON. THIS IS ONE OF THE SPECIAL QUARTERLY “UNLOCKED” EPISODES. In this episode: Jen shares stories clients who left their kooky therapists after one session, ghosting her own therapist after a decade, everyone is mad at Marie Kondo for giving up cleaning, advice for people with ADHD, Jen's final conclusion in the search for the perfect day planner - ends up being a realization that she's addicted to finding one and two women have invented a divorce registry to help friends start over with new stuff. To join Jen's Patreon go here: patreon.com/jenkirkmanTo join Jen's free newsletter go here: http://www.jenkirkman.com/newsletterTo stream or buy Jen's last comedy album (2022) “OK, GEN-X” go here: https://800PGR.lnk.to/OKGenXINTo shop Jen's merchandise store go here: http://jenkirkman.merchcentral.com/To buy Jen a coffee go here: https://www.buymeacoffee.com/JenkirkmanSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.